Bank Julius Baer & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank Julius Baer & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-555	Closed	-$102K	–	883
2021 Q2	$102K	Sell	555 -3,182	-85%	-$546K	﹤0.01%	635
2021 Q1	$571K	Buy	3,737 +3,059	+451%	+$473K	﹤0.01%	424
2020 Q4	$106K	Buy	+678	New	+$87.1K	﹤0.01%	620

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Bank Julius Baer & Co's ALXN Position: Q3 2021 in Review

Bank Julius Baer & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 555 shares — an estimated $102K sold.

Bank Julius Baer & Co first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $571K in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Bank Julius Baer & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bank Julius Baer & Co sold 555 Alexion Pharmaceuticals shares in Q3 2021, an estimated $102K.
Bank Julius Baer & Co first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Bank Julius Baer & Co's Alexion Pharmaceuticals position peaked at $571K in Q1 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank Julius Baer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.